EA201691146A1 - Иммуногенное соединение - Google Patents

Иммуногенное соединение

Info

Publication number
EA201691146A1
EA201691146A1 EA201691146A EA201691146A EA201691146A1 EA 201691146 A1 EA201691146 A1 EA 201691146A1 EA 201691146 A EA201691146 A EA 201691146A EA 201691146 A EA201691146 A EA 201691146A EA 201691146 A1 EA201691146 A1 EA 201691146A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptide
region
amino acid
peptide region
addition
Prior art date
Application number
EA201691146A
Other languages
English (en)
Inventor
Бертранд Джордж
Original Assignee
ОЛТИММЬЮН ЮКей ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОЛТИММЬЮН ЮКей ЛИМИТЕД filed Critical ОЛТИММЬЮН ЮКей ЛИМИТЕД
Publication of EA201691146A1 publication Critical patent/EA201691146A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящая заявка имеет отношение к иммуностимулирующему соединению, содержащему иммуностимулирующий участок и пептидный участок. Пептидный участок не является иммуногеном, ассоциированным с болезнью. Кроме того, пептидный участок имеет аминокислотную последовательность, в которой 75% или менее остатков аминокислот являются гидрофобными и/или имеют изоэлектрическую точку 5 или больше. Соединения изобретения имеют отношение к решению проблемы системного распределения иммуностимуляторов, вызывающих нежелательные побочные действия. Изобретатели обнаружили, что физико-химические свойства иммуностимулятора могут контролироваться ковалентной связью с пептидом. В дополнение к этому физико-химические свойства могут быть изменены полезным образом путем привнесения дополнительных свойств.
EA201691146A 2013-12-02 2014-12-02 Иммуногенное соединение EA201691146A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1321242.8A GB201321242D0 (en) 2013-12-02 2013-12-02 Immunogenic compound
PCT/GB2014/053577 WO2015082905A1 (en) 2013-12-02 2014-12-02 Immunogenic compound

Publications (1)

Publication Number Publication Date
EA201691146A1 true EA201691146A1 (ru) 2016-12-30

Family

ID=49979653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691146A EA201691146A1 (ru) 2013-12-02 2014-12-02 Иммуногенное соединение

Country Status (10)

Country Link
US (4) US9962453B2 (ru)
EP (1) EP3077052A1 (ru)
JP (2) JP6792452B2 (ru)
KR (1) KR102356869B1 (ru)
CN (1) CN105873638A (ru)
BR (1) BR112016012528A2 (ru)
CA (1) CA2931933A1 (ru)
EA (1) EA201691146A1 (ru)
GB (1) GB201321242D0 (ru)
WO (1) WO2015082905A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
CN115317603A (zh) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US11464854B2 (en) * 2017-03-23 2022-10-11 Children's Medical Center Corporation Methods and compositions relating to adjuvants
ES2951817T3 (es) 2017-08-22 2023-10-25 Dynavax Tech Corp Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos
EP3710059A1 (en) 2017-11-14 2020-09-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
CN112423787A (zh) * 2018-07-10 2021-02-26 思齐乐私人有限公司 团聚物的去除
KR20220004634A (ko) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Her2를 표적으로 하는 면역접합체
EP3946635A2 (en) * 2019-04-01 2022-02-09 Altimmune Uk Limited Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
WO2023239887A1 (en) * 2022-06-09 2023-12-14 Academia Sinica Nod1 modulators and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
FR2744123B1 (fr) * 1996-01-26 1998-04-17 Carelli Claude Marcel Henri Molecules biologiquement actives plus particulierement peptidiques ayant un effet potentialisateur de l'activite biologique de l'hormone de croissance
IL161786A0 (en) 2001-11-29 2005-11-20 3M Innovative Properties Co Pharmaceutical formulations comprising an immune
CN1671412B (zh) 2002-08-15 2010-05-26 3M创新有限公司 免疫刺激组合物及刺激免疫反应的方法
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CA2605808A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
PT2510946E (pt) 2007-02-07 2015-11-23 Univ California Conjugados de agonistas sintéticos de tlr e suas utilizações
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
MX2011004249A (es) 2008-10-24 2011-07-20 Glaxosmithkline Biolog Sa Derivados de imidazoquinolina lipidados.
EP2387421A1 (en) * 2009-01-14 2011-11-23 SKU Asset Management GmbH Compounds comprising n-formyl-methionine residues and tumor-targeting peptides
WO2011068233A1 (en) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
EP3222621B1 (en) 2010-08-17 2023-03-08 3M Innovative Properties Company Lipidated immune response modifier compound and its medical use
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound

Also Published As

Publication number Publication date
CA2931933A1 (en) 2015-06-11
US10434183B2 (en) 2019-10-08
GB201321242D0 (en) 2014-01-15
US20160310603A1 (en) 2016-10-27
WO2015082905A1 (en) 2015-06-11
US20200038519A1 (en) 2020-02-06
JP7095053B2 (ja) 2022-07-04
US9962453B2 (en) 2018-05-08
JP6792452B2 (ja) 2020-11-25
CN105873638A (zh) 2016-08-17
JP2021020967A (ja) 2021-02-18
KR20160113104A (ko) 2016-09-28
US10849984B2 (en) 2020-12-01
BR112016012528A2 (pt) 2017-09-26
JP2016540050A (ja) 2016-12-22
EP3077052A1 (en) 2016-10-12
US20190125889A1 (en) 2019-05-02
KR102356869B1 (ko) 2022-01-27
US20210145975A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
EA201691146A1 (ru) Иммуногенное соединение
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
WO2017030823A3 (en) Anti-tigit antibodies
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
EA201990071A1 (ru) Композиция пептидной вакцины
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
PH12015501620A1 (en) Pharmaceutical composition with improved bioavailability
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
EA201591839A1 (ru) Терапевтические пептиды
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EP3889185A3 (en) Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
WO2015033302A3 (en) Fulvestrant compositions
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015198240A3 (en) Compositions and methods for long acting proteins
EA201992832A1 (ru) Подкожное введение adamts13
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
SG10201805039UA (en) Protease resistant peptides
MX2019004116A (es) Metodo de preparacion de peptidos que comprenden una cadena lateral de lisina modificada lipofilicamente.